Immunology Laboratories, Inc. (ImmLab)

• ImmLab is a small, closely held Company located in Birmingham, Alabama, U.S.A.


• ImmLab was founded in 1997 and incorporated in Alabama, USA in 1998.


• ImmLab performs continuous research in Immunology, Microbiology and Proteomics of its present and future products at ImmLab's subsidiary in Europe in the Czech Republic.


• ImmLab has novel technological inventions for the prevention and treatment of staphylococcal infections in humans and animals.


• ImmLab products are the staphylococcal-lysates vaccines for prevention and treatment of staphylococcal infections in humans, companion and farm animals.


• In ImmLab's pipeline are ST398 MRSA human and porcine vaccines, as well as several other patents.


• With its patented technology, ImmLab is able to develop new products in reaction to actual epidemiological situation due to emerging resistant bacterial strains.


• At the present time the ImmLab owns five United States patents and ten international patents. The two new U.S. patents are in continuation status.


• ImmLab has substantially completed the preclinical stage for several of its products.


• ImmLab is interested in creating a partnering, merge or acquisition relationship.